Functional Efficacy of Dystrophin Expression from Plasmids Delivered to mdx Mice by Hydrodynamic Limb Vein Injection
Open Access
- 8 January 2010
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 21 (2) , 221-237
Abstract
In these studies we delivered by hydrodynamic limb vein (HLV) injection plasmid DNA (pDNA) expressing the full-length mouse dystrophin gene to skeletal muscles throughout the hind limbs of the mdx mouse model for Duchenne muscular dystrophy (DMD). We evaluated the levels and stability of dystrophin expression and measured the resulting muscle protection, using Evans blue dye (EBD) to mark the damaged myofibers. Plasmid delivery was as efficient in the dystrophic mice as in wild-type mice and equally efficient in young adult and old mice, as long as the dose of pDNA was adjusted for the target muscle weight. The HLV gene delivery procedure was tolerated well by the dystrophic mice and repeat injections could be performed over an extended period of time. Multiple gene deliveries additively increased the amount of dystrophin protein and also increased the percentages of dystrophin-expressing myofibers. Plasmids expressing dystrophin from a cytomegalovirus (CMV) promoter construct containing the HMG1 intron provided stable dystrophin expression for the life of the mouse and provided significant benefit to the limbs. EBD staining showed that dystrophin gene delivery preserved myofibers in the CMV-HMGi-mDys-injected leg by 2.5- to 5-fold in large groups of muscles and by 2.5-fold throughout the injected legs, compared with the contralateral control legs injected with a nonexpressing plasmid. A similar degree of protection was measured in young adult mice evaluated soon after the last gene delivery and in aged mice injected over an extended period of time. This degree of protection resulted from 18 to 20% of the normal level of dystrophin protein, with 11–16% dystrophin-expressing myofibers. These studies show promise for the use of HLV injections to deliver therapeutic doses of full-length dystrophin-expressing plasmids for long-lasting protection of skeletal muscles in patients with DMD.Keywords
This publication has 67 references indexed in Scilit:
- Muscular Gene Transfer Using Nonviral VectorsCurrent Gene Therapy, 2008
- Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vectorGene Therapy, 2008
- First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidantNeuromuscular Disorders, 2006
- Improved Production and Purification of Minicircle DNA Vector Free of Plasmid Bacterial Sequences and Capable of Persistent Transgene Expression In VivoHuman Gene Therapy, 2005
- Function and Genetics of Dystrophin and Dystrophin-Related Proteins in MusclePhysiological Reviews, 2002
- Animal models for muscular dystrophy: valuable tools for the development of therapiesHuman Molecular Genetics, 2000
- Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx miceGene Therapy, 2000
- Muscle fibers of mdx mice are more vulnerable to exercise than those of normal miceNeuromuscular Disorders, 1997
- Human dystrophin expression in mdx mice after intramuscular injection of DNA constructsNature, 1991
- X chromosome-linked muscular dystrophy (mdx) in the mouse.Proceedings of the National Academy of Sciences, 1984